同种脾细胞输注治疗血友病甲  

Allogenic splenic infusion for the treatment of hemophilia A

作　　者：刘慎微[1] 刘乐欣[1] 姜汉英[1] 马绪娴[1] 王滔[1] 夏穗生[1] 

机构地区：[1]同济医科大学附属同济医院,瑞典隆德大学医学院

出　　处：《中华器官移植杂志》1995年第2期79-80,共2页Chinese Journal of Organ Transplantation

摘　　要：我院１９８６年７月至１９９２年１２月对４０例重型血友病甲施行了５９次同种脾细胞输注，结果除２例血浆Ⅷ因子水平不升外，其余输注后２～７天Ⅷ因子水平均明显升高，平均升高５～２０．１％，最高１例达６１．７％，Ⅷ因于水平一般于输后４～８周逐渐下降。４０例受者中有９例反复输注脾细胞２～３次，每次间隔半个月至５个月不等，重复输注后可使Ⅷ因子再度上升，此法简便、安全、反复输注可弥补远期疗效不佳的缺点。times of allogenic splenic cell infusion were performed in 40 cases with severe hemophilia A from July 1986 to December 1990.The serum level of factor Ⅷ:C were increased significantly at 2ed-7th day after infusion in all cases but 2 with an average level of 5～20. 1% and highest, 61.7%,and then decreased slowly after 4～8 weeks. In 9 cases.the second or third infusion were performed with an interval of 15 days to 5 months.The repeated infusion could make the level of factor Ⅷ:C rise again and maintained for 1 to 12 months. Allogenic splenic cell infusion is considered to be a safe. simple and effective new treatment for hemophilia A, and the repeated infusion may remedy the defect of relatively short effect of single infusion.

关 键 词：血友病 脾细胞输注 血友病甲 VIII因子 治疗 

分 类 号：R554.105[医药卫生—血液循环系统疾病]